Cell signaling abnormalities in cardiomyopathy caused by lamin A/C gene mutations

Area of Science:

• Molecular Biology
• Cardiovascular Medicine
• Genetics

Background:

• Mutations in the lamin A/C gene (LMNA) cause laminopathies, a group of genetic disorders.
• These mutations primarily affect the inner nuclear membrane proteins, leading to dilated cardiomyopathy and skeletal myopathy.
• LMNA mutations are linked to cellular signaling dysregulation in cardiac tissue.

Purpose of the Study:

• To investigate cell signaling abnormalities in mouse models of LMNA mutation-induced cardiomyopathy.
• To identify specific signaling pathways contributing to the pathogenesis of laminopathies.
• To explore potential therapeutic targets for treating human laminopathies.

Main Methods:

• Analysis of cell signaling pathways in cardiac tissue from mouse models with LMNA mutations.
• Focus on mitogen-activated protein kinases (MAPK), protein kinase B/mammalian target of rapamycin complex 1 (Akt/mTORC1), and transforming growth factor-beta (TGF-β) signaling.

Main Results:

• Abnormally increased signaling was observed in extracellular signal-regulated kinase 1 and 2 (ERK1/2) and other MAPKs.
• Elevated signaling in the protein kinase B/mammalian target of rapamycin complex 1 (Akt/mTORC1) pathway was detected.
• Increased transforming growth factor-beta (TGF-β) signaling was also identified in affected hearts.

Conclusions:

• LMNA mutations associated with laminopathies lead to significant cell signaling pathway dysregulation in the heart.
• Aberrant MAPK, Akt/mTORC1, and TGF-β signaling contribute to the pathogenesis of these cardiomyopathies.
• Targeted inhibition of these activated signaling pathways represents a potential therapeutic strategy for laminopathies.